Novo Nordisk A/S (NVO) Projected to Release Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Novo Nordisk A/S to announce earnings of $0.77 per share and revenue of $10.8986 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, analysts expect Novo Nordisk A/S to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $47.12 on Tuesday. The company has a market cap of $210.37 billion, a PE ratio of 11.06, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $46.96 and a 200-day moving average price of $45.32. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Reuters reports that Novo may be beginning to regain ground in the obesity-drug race with Eli Lilly, offering investors a potential recovery narrative after two difficult years of profit warnings, leadership changes and declining share performance. Obesity battle heats up again as Novo claws way back into race with Lilly
• Neutral Sentiment: Citi maintained a neutral rating, saying the market’s reaction to the failed ZEUS heart-drug trial may have been excessive. However, the bank remains on the sidelines because of concerns about obesity-drug pricing, competition and the durability of GLP-1 growth. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines
• Neutral Sentiment: Novo is approaching its second-quarter earnings report with investors looking for evidence that demand for injectable GLP-1 medicines is stabilizing. Results and management guidance will be important for assessing whether recent weakness reflects temporary pressure or a broader slowdown. Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
• Negative Sentiment: Novo disclosed that ziltivekimab failed to meet the primary endpoint in the Phase 3 ZEUS trial, failing to reduce major adverse cardiovascular events versus placebo. The setback weakens hopes of diversifying growth beyond weight-loss drugs and contributed to the recent decline in investor sentiment. Novo Nordisk shares in hot water after disappointing trial
• Negative Sentiment: Eli Lilly’s upcoming results are another near-term risk: strong Mounjaro and Zepbound sales could reinforce Lilly’s competitive advantage, while early demand for its obesity product Foundayo will be watched closely by investors comparing the two companies. Will Mounjaro and Zepbound Drive Lilly’s Q2 Results

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $65.56.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of the company. Revolve Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. Sivia Capital Partners LLC boosted its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after buying an additional 1,587 shares during the period. Golden State Wealth Management LLC grew its holdings in Novo Nordisk A/S by 59.1% in the 4th quarter. Golden State Wealth Management LLC now owns 2,389 shares of the company’s stock worth $122,000 after acquiring an additional 887 shares during the last quarter. Gilpin Wealth Management LLC bought a new stake in Novo Nordisk A/S in the 4th quarter worth $67,000. Finally, Palisade Asset Management LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at about $110,000. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.